0001144204-17-001882.txt : 20170111
0001144204-17-001882.hdr.sgml : 20170111
20170111201923
ACCESSION NUMBER: 0001144204-17-001882
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170109
FILED AS OF DATE: 20170111
DATE AS OF CHANGE: 20170111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nuo Therapeutics, Inc.
CENTRAL INDEX KEY: 0001091596
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 233011702
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 207A PERRY PARKWAY,
STREET 2: SUITE 1
CITY: GAITHERSBURG,
STATE: MD
ZIP: 20877
BUSINESS PHONE: 240-499-2680
MAIL ADDRESS:
STREET 1: 207A PERRY PARKWAY,
STREET 2: SUITE 1
CITY: GAITHERSBURG,
STATE: MD
ZIP: 20877
FORMER COMPANY:
FORMER CONFORMED NAME: Nuo Therapeutics, Inc
DATE OF NAME CHANGE: 20141112
FORMER COMPANY:
FORMER CONFORMED NAME: CYTOMEDIX INC
DATE OF NAME CHANGE: 20000511
FORMER COMPANY:
FORMER CONFORMED NAME: AUTOLOGOUS WOUND THERAPY INC
DATE OF NAME CHANGE: 20000407
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JORDEN DAVID EMERSON
CENTRAL INDEX KEY: 0001313516
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32518
FILM NUMBER: 17523821
MAIL ADDRESS:
STREET 1: 2635 TECHNOLOGY FOREST BLVD.
CITY: THE WOODLANDS
STATE: TX
ZIP: 77381
4
1
v456665_4.xml
OWNERSHIP DOCUMENT
X0306
4
2017-01-09
0
0001091596
Nuo Therapeutics, Inc.
NONE
0001313516
JORDEN DAVID EMERSON
C/O NUO THERAPEUTICS, INC.
207A PERRY PKWY STE 1
GAITHERSBURG
MD
20877
1
1
0
0
CEO, CFO
Option to purchase Common Stock
1.00
2017-01-09
4
A
0
162500
0
A
2026-07-01
Common Stock
162500
162500
D
The grant of these options was approved by the issuer's board of directors on July 1, 2016, subject to stockholder approval of the 2016 Omnibus Incentive Compensation Plan under which the options were granted. Stockholder approval was obtained by means of a written consent and the issuer filed a related Information Statement on Schedule 14C with the SEC on November 25, 2016. The stockholder approval became effective on January 9, 2017. The option grant disclosed herein does not include options to purchase 187,500 shares subject to performance conditions, which have not yet vested and are therefore not yet reportable on Form 4.
Of these options, 62,500 vested immediately, and 50,000 each will vest on 3/31/17 and 12/31/17.
/s/ David E. Jorden
2017-01-11